Recent News

• 09.09.2025 - Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
• 09.09.2025 - Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
• 08.14.2025 - Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
• 08.14.2025 - Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
• 08.06.2025 - Daina Graybosch
• 08.06.2025 - Daina Graybosch
• 08.01.2025 - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.01.2025 - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 07.02.2025 - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 07.02.2025 - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 08.28.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 8-K Current report
• 08.14.2025 - EX-99.1 EX-99.1
• 06.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2025 - 4/A Statement of changes in beneficial ownership of securities